The present study aims to assess the impact of the development of neutropenia (with 1st cycle) and dose reduction in addition to different clinicopathological factors such as ECOG PS and HER2 low status, on the outcome of the first-line therapy of palbociclib with hormonal therapy in HR-positive/HER2-negative metastatic breast cancer patients. Here, ERBB2 is linked to neutropenia.